〔Abstract〕 Objective To investigate the clinical efficacy of using zoledronic acid combined with tebrurone in osteoporosis in postmenopausal women. Methods 120 women patients with osteoporosis were treated in Dongguan Zhongtang Hospital from September 2018 to January 2020. The randomized digital table was divided into control group, tebron treatment group (A group), zoledronic acid treatment group (B). 30 patients each observed and compared bone metabolic function changes and adverse reactions during treatment. Results Before treatment, osteocalin, serotype precollagen peptide (CTX), bone alkaline phosphatase (BALP) and pain score comparison (P > 0.05). After treatment, they were significantly improved (P < 0.05). Higher rates of adverse reactions in A and C than in controls were statistically significant (P < 0.05); higher than in A and B, and statistically significant (P < 0.05). The incidence of brittle fractures was significantly lower than in control groups, and the difference was statistically significant (P < 0.05). The incidence of brittle fractures was significantly lower in the B and C than in the controls (P < 0.05); and the incidence of brittle fracture (P > 0.05). Conclusion The treatment of osteoporosis zoledronic acid with tebolone can improve the bone metabolic function.